KEIUi001-A

Registration Summary:

A P E C

The cell line is not submitted yet.

(only basic data is shown)

General

Cell Line
hPSCreg name	KEIUi001-A
Cite as:	KEIUi001-A (RRID:CVCL_A1YC)
Cell line type	Human induced pluripotent stem cell (hiPSC)
Similar lines	No similar lines found.
Last update	9th November 2020
User feedback	Written by on No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Keio University (KEIU)
External Databases
Cellosaurus	CVCL_A1YC
Wikidata	Q105509773
General Information
Publications	Ohta E et al. Generation of gene-corrected iPSCs line (KEIUi001-A) from a PARK8 patient iPSCs with familial Parkinson's disease carrying the I2020T mutation in LRRK2. Stem cell research. 2020 Dec;49:102073. Zhu X et al. Gene Therapy for Neurodegenerative Disease: Clinical Potential and Directions. Frontiers in molecular neuroscience. 2021;14:618171. Rahman MU et al. CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease. Pharmaceutics. 2022 Jun 13;14(6). Hattori A et al. A new approach to analysis of intracellular proteins and subcellular localization using cellprofiler and imageJ in combination. Methods (San Diego, Calif.). 2022 Jul;203:233-241. Gao Jingjing et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nature Reviews Neuroscience. 2024-08-00. Malviya Rishabha et al. Gene Therapy for Neurological Disorders. . 2024-10-04. Kumar Ankur et al. Therapeutic potential of genome editing tools in neurodegenerative diseases. Genome Editing for Neurodegenerative Diseases. 2025-00-00. Mishra Shailendra Kumar et al. Advances in CRISPER/Cas system and genome editing technologies for the treatment of neurodegenerative diseases. Genome Editing for Neurodegenerative Diseases. 2025-00-00. Huang Chen-Wei et al. A targeted approach: Gene and RNA editing for neurodegenerative disease treatment. Life Sciences. 2025-09-00.

hIPSC Derivation

General